0001246360-19-000743.txt : 20190225 0001246360-19-000743.hdr.sgml : 20190225 20190225155611 ACCESSION NUMBER: 0001246360-19-000743 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190221 FILED AS OF DATE: 20190225 DATE AS OF CHANGE: 20190225 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: LEWIS EARL R CENTRAL INDEX KEY: 0001230427 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-51567 FILM NUMBER: 19629369 MAIL ADDRESS: STREET 1: C/O NXSTAGE MEDICAL INC. (NXTM) STREET 2: 439 SOUTH UNION STREET, 5TH FLOOR CITY: LAWRENCE STATE: MA ZIP: 01843 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: NxStage Medical, Inc. CENTRAL INDEX KEY: 0001333170 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 043454702 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 350 MERRIMACK STREET CITY: LAWRENCE STATE: MA ZIP: 01843 BUSINESS PHONE: 978-687-4700 MAIL ADDRESS: STREET 1: 350 MERRIMACK STREET CITY: LAWRENCE STATE: MA ZIP: 01843 4 1 form.xml PRIMARY DOCUMENT X0306 4 2019-02-21 true 0001333170 NxStage Medical, Inc. NXTM 0001230427 LEWIS EARL R 350 MERRIMACK STREET LAWRENCE MA 01843 true false false false Common Stock 2019-02-21 4 D false 100232 30 D 0 D Stock Option (Right to Buy) 13.16 2019-02-21 4 D false 23394 0 D 2014-05-22 2024-05-21 Common Stock 23394 0 D Stock Option (Right to Buy) 16.81 2019-02-21 4 D false 19724 0 D 2015-06-21 2025-05-20 Common Stock 19724 0 D Stock Option (Right to Buy) 18.32 2019-02-21 4 D false 15854 0 D 2016-06-26 2023-05-25 Common Stock 15854 0 D Stock Option (Right to Buy) 22.78 2019-02-21 4 D false 15643 0 D 2017-06-25 2024-05-24 Common Stock 15643 0 D Disposed of under Merger Agreement with Fresenius Medical Care Holdings, Inc. in which all outstanding shares of Issuer's Common Stock were converted into the right to receive $30 per share in cash. This option was canceled in the Merger in exchange for an amount in cash equal to the product of the total number of shares subject to the option multiplied by the excess of the Merger Consideration of $30 per share over the option exercise price. /s/ Aras Lapinskas, attorney-in-fact for Earl Lewis 2019-02-25